Instruction 1(b)

## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, I	D.C.	20549
---------------	------	-------

	CTATEMENT OF CHANGES IN DENEELOIAL CHANEDOLUS
Check this box if no longer subject to	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Section 16. Form 4 or Form 5	
obligations may continue. See	

OMB APPROVAL OMB Number: Estimated average burden

0.5

hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Bradway Robert A</u>			2. Issuer Name <b>and</b> Ticker or Trading Symbol  AMGEN INC [ AMGN ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)									
												X Dire		ctor 10%		10% C	wner				
(Last)	(Fi	rst) (	(Middle)				Date of Earliest Transaction (Month/Day/Year)								X		Officer (give title below)		Other below)	(specify	
ONE AMGEN CENTER DRIVE				03/03/2020									Chairman, CEO and President								
(Street) THOUSA OAKS	AND CA	A 9	91320-1799			4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person						
————											Form filed by More than One Reporting Person										
(City)	(St	ate) (	Zip)																		
		Tabl	e I - Nor	า-Deriv	ative	Sec	curitie	s Acc	uired,	Dis	posed o	f, or	Bene	eficia	ally (	Owne	ed				
Date				Date	th/Day/Year) i		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Dispose Code (Instr. 5)		rities Acquired (A) d Of (D) (Instr. 3,			4 and Sec Bei Ow		Securities Beneficially		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code			v	Amount		(A) or (D)	Price	. 1	Transaction(s) (Instr. 3 and 4)				(1130.4)		
Common Stock				03/03/2020					A		55,68	3	A	\$0		524,066(1)(2)		Г	)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
Derivative Conversion Date Executi Security or Exercise (Month/Day/Year) if any		3A. Deeme Execution if any (Month/Da	n Date, Transaction Code (Insti					6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)  Amour or Numbe		ount	Deriv Secu	Price of rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	n: ct (D) ndirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)		Date Exercisal		Expiration Date	Title	of Sha	res								

## **Explanation of Responses:**

1. These shares include the following RSUs granted under the Company's equity plans: 4,784 RSUs which vest on 5/3/2020; 9,890 RSUs which vest in installments of 4,871 on 5/1/2020 and 5,019 on 5/1/2021; 14,087 RSUs which vest in installments of 4,648 on 4/27/2020, 4,649 on 4/27/2021 and 4,790 on 4/27/2022; and 15,791 RSUs which vest in two installments of 5,211 on 5/3/2021 and 5/3/2022 and one installment of 5,369 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

(A) (D) Exercisable Date

/s/ Robert A. Bradway 03/04/2020

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>2.</sup> These shares include 2,374 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.